These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 31506195)

  • 1. Protective immunity against influenza virus challenge by norovirus P particle-M2e and HA2-AtCYN vaccines in chickens.
    Elaish M; Xia M; Ngunjiri JM; Ghorbani A; Jang H; Kc M; Abundo MC; Dhakal S; Gourapura R; Jiang X; Lee CW
    Vaccine; 2019 Oct; 37(43):6454-6462. PubMed ID: 31506195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterosubtypic protection against avian influenza virus by live attenuated and chimeric norovirus P-particle-M2e vaccines in chickens.
    Ghorbani A; Ngunjiri JM; Xia M; Elaish M; Jang H; Mahesh KC; Abundo MC; Jiang X; Lee CW
    Vaccine; 2019 Feb; 37(10):1356-1364. PubMed ID: 30691981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and protective efficacy of the norovirus P particle-M2e chimeric vaccine in chickens.
    Elaish M; Kang KI; Xia M; Ali A; Shany SA; Wang L; Jiang X; Lee CW
    Vaccine; 2015 Sep; 33(38):4901-9. PubMed ID: 26232342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Supplementation of inactivated influenza vaccine with norovirus P particle-M2e chimeric vaccine enhances protection against heterologous virus challenge in chickens.
    Elaish M; Ngunjiri JM; Ali A; Xia M; Ibrahim M; Jang H; Hiremath J; Dhakal S; Helmy YA; Jiang X; Renukaradhya GJ; Lee CW
    PLoS One; 2017; 12(2):e0171174. PubMed ID: 28151964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy.
    Kim SM; Kim YI; Park SJ; Kim EH; Kwon HI; Si YJ; Lee IW; Song MS; Choi YK
    J Virol; 2017 Mar; 91(6):. PubMed ID: 28077631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of an Inactivated H7N9 Subtype Avian Influenza Serological DIVA Vaccine Using the Chimeric HA Epitope Approach.
    Sun Z; Wang Q; Li G; Li J; Chen S; Qin T; Ma H; Peng D; Liu X
    Microbiol Spectr; 2021 Oct; 9(2):e0068721. PubMed ID: 34585985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice.
    Kim EH; Park HJ; Han GY; Song MK; Pereboev A; Hong JS; Chang J; Byun YH; Seong BL; Nguyen HH
    J Virol; 2014 Sep; 88(17):9693-703. PubMed ID: 24920793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
    Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
    Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the immunogenicity and protective effects of a trivalent chimeric norovirus P particle immunogen displaying influenza HA2 from subtypes H1, H3 and B.
    Gong X; Yin H; Shi Y; He X; Yu Y; Guan S; Kuai Z; Haji NM; Haji NM; Kong W; Shan Y
    Emerg Microbes Infect; 2016 May; 5(5):e51. PubMed ID: 27222326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral immunization with an attenuated
    Hajam IA; Kirthika P; Hewawaduge C; Jawalagatti V; Park S; Senevirathne A; Lee JH
    Avian Pathol; 2020 Oct; 49(5):486-495. PubMed ID: 32483989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
    Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
    Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Supplemented vaccination with tandem repeat M2e virus-like particles enhances protection against homologous and heterologous HPAI H5 viruses in chickens.
    Song BM; Kang HM; Lee EK; Jung SC; Kim MC; Lee YN; Kang SM; Lee YJ
    Vaccine; 2016 Jan; 34(5):678-686. PubMed ID: 26691568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination with different M2e epitope densities confers partial protection against H5N1 influenza A virus challenge in chickens.
    Zhang X; Liu M; Liu C; Du J; Shi W; Sun E; Li H; Li J; Zhang Y
    Intervirology; 2011; 54(5):290-9. PubMed ID: 21228535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus.
    Kapczynski DR; Esaki M; Dorsey KM; Jiang H; Jackwood M; Moraes M; Gardin Y
    Vaccine; 2015 Feb; 33(9):1197-205. PubMed ID: 25613723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant Lactobacillus plantarum expressing HA2 antigen elicits protective immunity against H9N2 avian influenza virus in chickens.
    Yang WT; Yang GL; Yang X; Shonyela SM; Zhao L; Jiang YL; Huang HB; Shi CW; Wang JZ; Wang G; Zhao JH; Wang CF
    Appl Microbiol Biotechnol; 2017 Dec; 101(23-24):8475-8484. PubMed ID: 29090342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and Protective Potential of Mucosal Vaccine Formulations Based on Conserved Epitopes of Influenza A Viruses Fused to an Innovative Ring Nanoplatform in Mice and Chickens.
    Calzas C; Mao M; Turpaud M; Viboud Q; Mettier J; Figueroa T; Bessière P; Mangin A; Sedano L; Hervé PL; Volmer R; Ducatez MF; Bourgault S; Archambault D; Le Goffic R; Chevalier C
    Front Immunol; 2021; 12():772550. PubMed ID: 34868036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses.
    Kapczynski DR; Pantin-Jackwood MJ; Spackman E; Chrzastek K; Suarez DL; Swayne DE
    Vaccine; 2017 Nov; 35(46):6345-6353. PubMed ID: 28456525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The highly conserved HA2 protein of the influenza A virus induces a cross protective immune response.
    Lee JS; Chowdhury MY; Moon HJ; Choi YK; Talactac MR; Kim JH; Park ME; Son HY; Shin KS; Kim CJ
    J Virol Methods; 2013 Dec; 194(1-2):280-8. PubMed ID: 24004822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of M2e peptide with stalk HA epitopes of influenza A virus enhances protective properties of recombinant vaccine.
    Tsybalova LM; Stepanova LA; Shuklina MA; Mardanova ES; Kotlyarov RY; Potapchuk MV; Petrov SA; Blokhina EA; Ravin NV
    PLoS One; 2018; 13(8):e0201429. PubMed ID: 30138320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective efficacy of an inactivated chimeric H5 avian influenza vaccine against H5 highly pathogenic avian influenza virus clades 2.3.4.4 and 2.3.2.1.
    Li J; Hou G; Wang Y; Wang S; Cheng S; Peng C; Jiang W
    J Gen Virol; 2018 Dec; 99(12):1600-1607. PubMed ID: 30358528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.